Molecular Partners
MOLN
8 hedge funds and large institutions have $3.91M invested in Molecular Partners in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 0 closing their positions.
14% more funds holding
Funds holding: 7 → 8 (+1)
0% less capital invested
Capital invested by funds: $3.91M → $3.91M (-$380)
0.01% less ownership
Funds ownership: 2.64% → 2.63% (-0.01%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$4 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$16.6K |
MOLN Hedge Fund Activity: Q4 2023 in Review
8 of the 6,868 institutional investors tracked by Wall St. Rank reported a position in Molecular Partners (MOLN) for Q4 2023, worth a combined $3.91M — down 0.01% from $3.91M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new MOLN positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.
The largest buyer was JP Morgan Chase, opening a new position worth an estimated $4. The largest seller was Susquehanna International Group, cutting an estimated $16.6K.
- 8 institutional investors held Molecular Partners (MOLN) as of Q4 2023, up from 7 in Q3 2023.
- Funds reported $3.91M of Molecular Partners stock for Q4 2023, down 0.01% quarter-over-quarter.
- 1 fund opened new Molecular Partners positions in Q4 2023 and 0 closed out, a net change of +1 holder.
- The largest Molecular Partners buyer in Q4 2023 was JP Morgan Chase, an estimated $4 added.
- The largest Molecular Partners seller in Q4 2023 was Susquehanna International Group, an estimated $16.6K sold.
Based on aggregated 13F filings for Q4 2023.